Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus chemotherapy in advanced esophageal or gastric/GEJ cancer
CTR20170515Phase 2Completed
- Sponsor
- BeiGene
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by BeiGene. Started Jun 2017; status: completed.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20170515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170515.